These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35172056)

  • 1. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
    N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
    N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral GS-5806 activity in a respiratory syncytial virus challenge study.
    DeVincenzo JP; Whitley RJ; Mackman RL; Scaglioni-Weinlich C; Harrison L; Farrell E; McBride S; Lambkin-Williams R; Jordan R; Xin Y; Ramanathan S; O'Riordan T; Lewis SA; Li X; Toback SL; Lin SL; Chien JW
    N Engl J Med; 2014 Aug; 371(8):711-22. PubMed ID: 25140957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    Schmoele-Thoma B; Zareba AM; Jiang Q; Maddur MS; Danaf R; Mann A; Eze K; Fok-Seang J; Kabir G; Catchpole A; Scott DA; Gurtman AC; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA
    N Engl J Med; 2022 Jun; 386(25):2377-2386. PubMed ID: 35731653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
    Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
    Ferrero F; Lin CY; Liese J; Luz K; Stoeva T; Nemeth A; Gijón M; Calvo C; Natalini S; Toh TH; Deleu S; Chen B; Rusch S; Sánchez BL; Leipoldt I; Vijgen L; Huntjens D; Baguet T; Bertzos K; Gamil M; Stevens M;
    Paediatr Drugs; 2024 Jul; 26(4):411-427. PubMed ID: 38649595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
    Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
    J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
    Nilsson AC; Pullman J; Napora P; Luz K; Gupta A; Draghi J; Guzman Romero AK; Aggarwal N; Petrova G; Ianus J; Vijgen L; Scott J; Sinha R; Rusch S; Huntjens D; Bertzos K; Stevens M;
    Clin Microbiol Infect; 2023 Oct; 29(10):1320-1327. PubMed ID: 37422079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo J; Cass L; Murray A; Woodward K; Meals E; Coates M; Daly L; Wheeler V; Mori J; Brindley C; Davis A; McCurdy M; Ito K; Murray B; Strong P; Rapeport G
    J Infect Dis; 2022 Jun; 225(12):2087-2096. PubMed ID: 33216113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    Sadoff J; De Paepe E; DeVincenzo J; Gymnopoulou E; Menten J; Murray B; Rosemary Bastian A; Vandebosch A; Haazen W; Noulin N; Comeaux C; Heijnen E; Eze K; Gilbert A; Lambkin-Williams R; Schuitemaker H; Callendret B
    J Infect Dis; 2022 Aug; 226(3):396-406. PubMed ID: 33400792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
    Martinón-Torres F; Rusch S; Huntjens D; Remmerie B; Vingerhoets J; McFadyen K; Ferrero F; Baraldi E; Rojo P; Epalza C; Stevens M
    Clin Infect Dis; 2020 Dec; 71(10):e594-e603. PubMed ID: 32201897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.
    Jordan E; Kabir G; Schultz S; Silbernagl G; Schmidt D; Jenkins VA; Weidenthaler H; Stroukova D; Martin BK; De Moerlooze L
    J Infect Dis; 2023 Oct; 228(8):999-1011. PubMed ID: 37079393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus].
    Reina J; Iglesias C
    Rev Esp Quimioter; 2023 Feb; 36(1):26-29. PubMed ID: 36401806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dexamethasone on tracheal viral load and interleukin-8 tracheal concentration in children with respiratory syncytial virus infection.
    van Woensel JB; Lutter R; Biezeveld M; Dekker T; Nijhuis M; van Aalderen WM; Kuijpers TW
    Pediatr Infect Dis J; 2003 Aug; 22(8):721-6. PubMed ID: 12913774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV.
    Stray K; Perron M; Porter DP; Anderson F; Lewis SA; Perry J; Miller M; Cihlar T; DeVincenzo J; Chien JW; Jordan R
    J Infect Dis; 2020 Oct; 222(9):1468-1477. PubMed ID: 31971597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Yang Z; Li Z; Zhan Y; Lin Z; Fang Z; Xu X; Lin L; Li H; Lin Z; Kang C; Liang J; Liang S; Li Y; Li S; Yang X; Ye F; Zhong N;
    Lancet Infect Dis; 2024 May; 24(5):535-545. PubMed ID: 38330975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.